MedTrace Logo

Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients

NCT01209403 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-09-30

No results posted yet for this study

Summary

The purpose of this study is to investigate whether the anabolic potentials of insulin may be used to reverse the catabolic effects of hemodialysis in non-diabetic patients with end-stage renal failure.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Glucose-infusion

Continuous iv infusion of glucose

DRUG

Glucose-insulin infusion

Continuous iv infusion of glucose and shortlasting

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Per Ivarsen, MD, PhD · Department of Nephrology, Aarhus University Hospital, Skejby

  • Jan Frystyk, MD,PhD,DMSc · Department of Endocrinology and Internal Medicine, Aarhus University Hospital

  • Bente Jespersen, MD, DMSc · Department of Nephrology, Aarhus University Hospital, Skejby

  • Mark Reinhard, MD · Department of Nephrology, Aarhus University Hospital, Skejby

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01209403 on ClinicalTrials.gov